Subtype
Endometrial Neoplasm
CI-CAN-00007648Explore in graph →
Non-malignant400 active trials4 approved drugs28 evidence items
Loading cancer entity…
Subtype
CI-CAN-00007648Explore in graph →
Clinical trials
1,340 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06805864 | Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma(BROTHER) | not yet recruiting | Phase 2 | 45 | Gunma UniversityOTHER | 1 | Feb 3, 2025 |
| NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 282 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06771154 | Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial(A-CAPE) | not yet recruiting | Phase 2 | 140 | Peking Union Medical College HospitalOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06751277 | QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer | not yet recruiting | Phase 2 | 26 | xiang yangOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)(SATELLITE) | recruiting | Phase 2 | 10 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06522828 | A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients | recruiting | Phase 2 | 80 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT04652076 | GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab(GYNET) | active not recruiting | Phase 1 / Phase 2 | 240 | NETRIS PharmaINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06620029 | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | not yet recruiting | Phase 1 / Phase 2 | 27 | BioMimetix JV, LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06014190 | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer | recruiting | Phase 2 | 460 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 29, 2024 | clinicaltrials |
| NCT01686126 | Improving the Treatment for Women With Early Stage Cancer of the Uterus(feMMe) | active not recruiting | Phase 2 | 165 | Queensland Centre for Gynaecological CancerOTHER_GOV | 2 | Aug 28, 2024 | clinicaltrials |
| NCT06548763 | Oral Topotecan With Toripalimab for Patients With Endometrial Cancer | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT06413992 | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | recruiting | Phase 2 | 117 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06066216 | Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer | not yet recruiting | Phase 2 | 45 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 23, 2024 | clinicaltrials |
| NCT04716686 | Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05550558 | Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer(CAN-RESPOND) | not yet recruiting | Phase 2 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Sep 28, 2022 | clinicaltrials |
| NCT05489848 | Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation | not yet recruiting | Phase 2 / Phase 3 | 294 | Fudan UniversityOTHER | 0 | Aug 5, 2022 | clinicaltrials |
| NCT03463252 | Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC | recruiting | Phase 2 / Phase 3 | 224 | West China Second University HospitalOTHER | 1 | Sep 13, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Feb 7, 2025source: clinicaltrials